cas 104737-00-0, 5-bromo-2-methyl-8-nitro-1,2,3,4-tetrahydroisoquinoline

Articles about 104737-00-0Total 22 be found

Article title
Article abstract
Author
Journal number and time
Download

Cyclizing Enamine-Iminium-Reaction
Treatment of 5-bromo-2-methyl-8-nitroisoquinolinium salt (1-X) with alkali leads to the pseudobase 3 as an intermediate which disproportionates to the lactam 6 and to the dihydroisoquinoline 7.On the other side the polycyclic compound 5 is built by an intermelecular reaction: the structure of 5 is elucidated.
Moehrle, Hans,Biegholdt, Martin
p. 817 - 820
(1988)
Read Online

ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, Ar, m and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
-
Page/Page column 25

(2010/02/17)

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
-
Page/Page column 69

(2010/04/03)

ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, Q, G, Ar, m, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
-
Page/Page column 52-53

(2010/03/02)

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
-
Page/Page column 87; 88

(2010/04/06)

PYRROLIDINE-SUBSTITUTED AZAINDOLE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, A, B, D, E, G, Ar, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
-
Page/Page column 35; 36

(2010/02/17)

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
-
Page/Page column 105-106

(2009/04/25)

COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS
The present invention is directed towards radiolabeled ASIC imaging agents of formula I as well as metabolites of ASIC antagonists under formula HI wherein n can be 0 or 1 These compounds are useful for the diagnosis and treatment of diseases or disorders related to the activity of gated ion channels, namely neurological disorders, pam and inflammatory disorders
-
Page/Page column 86

(2009/01/20)

4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, R6, B, D, E, G, Q, x and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
-
Page/Page column 23

(2009/01/24)

6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1—R4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
-
Page/Page column 45; 46

(2008/12/08)

COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
The present disclosure provides compounds having affinity for the 5HT6 receptor which are of the formula (I), wherein R1-R3 A, B, D, E, G, Q, and x are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
-
Page/Page column 127; 128

(2010/11/28)

COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS
Pyrrolo-isoquinoline compounds according to formula (I) wherein R3 is preferably a hydroxy radical and the southern ring is preferably a phenyl ring. These compounds and their pharmaceutical acceptable salts are used for modulating gated ion channels in order to treat pain, inflammatory disorders, neurological disorders, or diseases associated with the genitourinary or gastrointestinal systems.
-
Page/Page column 79

(2008/06/13)

COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS
The alleged invention relates to indole derivatives according to formula 1, namely, wherein X is CH2, O, NR2 or NOR2 and wherein A is preferably a six membered ring involving a nitrogen heteroatom. These compounds and their pharmaceutical acceptable salts are used for modulating gated ion channels in order to treat pain, inflammatory disorders, neurological disorders, or diseases associated with the genitourinary or gastrointestinal systems.
-
Page/Page column 139

(2008/06/13)

NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE
A compound having the formula or a pharmaceutically acceptable salt thereof wherein R is hydrogen or hydroxy; R1 is hydrogen, alkyl, arylalkyl, (CH2)nOH, or (CH2) NR7R8; R5 and R6 are each independently hydrogen, halogen, NO2, CN, CF3, SO2NR7R8, PO3R9R10, alkyl, alkenyl, alkynyl, (CH2)nCONR7R8, (CH2)nCO2R10, NHCOR11, wherein R7 and R8 are each independently hydrogen or alkyl or together R7 and R8 form a ring of from three to seven atoms, R9 is hydrogen or alkyl, R10 is hydrogen or alkyl, R11 is hydrogen or alkyl, and n is an integer of from zero to four; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b, and formed by the following bivalent radicals: a-NR12—CHR13—CHR14-b, a-CHR13—CHR14—NR12-b, a-CHR13—NR12—CHR14-b, a-CHR14—CH2—NR12—CHR13-b, a-CHR13—NR12—CH2—CHR14-b, a-CH2—CH2—CHR13—NR12-b, a-NR12—CHR12—CHR13—CH2—CH2-b, a-CH2—CH2—NR12—CH2—CH2-b, a-CH2—CH2—CH2NR12—CH2-b, a-CH2—NR12—CH2—CH2-b a-CH2—CH2—CH2—CH2—NR12-b, a-NR12—CH2—CH2—CH2—CH2-b, wherein R12 is hydrogen, CH2CH2OH, or alkyl, and R13 and R14 are each independently hydrogen, CN, CONH2, CH2NH2, CH2OH, alkyl, arylalkyl, alkenyl, or CO2R15, wherein R15 is hydrogen or alkyl. The compounds are useful in the treatment of disorders of mammals, responsive to the blockade of glutamic and aspartic acid receptors. Processes for preparing the compounds and novel intermediate useful in the processes are also included.
-
(2008/06/13)

Isatine derivatives with neurotrophic activity
The present invention relates to novel isatin derivatives, pharmaceutical compositions comprising the isatin derivatives of the invention, methods of preparing the isatin derivatives of the invention, their use in the treatment of neurodegenerative diseas
-
(2008/06/13)

Indole-2,3-dione-3-oxime derivatives, their preparation and use
The present patent application discloses compounds having the formula STR1 or a pharmaceutically acceptable salt thereof wherein R1, X and R5 have the meanings set further in the specification. A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b. The compounds are useful in the treatment of cerebrovascular disorders for example.
-
(2008/06/13)

Fused indole and quinoxaline derivatives, their preparation and use
The present patent application discloses compounds having the formula STR1 or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, alkyl or benzyl; X is O or NOR2, wherein R2 is hydrogen, alkyl or benzyl; Y is N--R4 wherein R4 is hydrogen, OH or alkyl; n is 0 or 1; R6 is phenyl which is substituted one or more times with substituents selected from the group consisting of SO2 NR'R", CONR'R", and COR'" wherein R' and R" each independently are hydrogen, alkyl, or --(CH2)p --W, wherein p is 0, 1, 2, 3, 4, 5, or 6, and W is hydroxy, amino, alkoxycarbonyl, or phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, NO2, amino, alkyl, alkoxy or methylenedioxy; or wherein R' and R" together is (CH2)r Z(CH2)s wherein r and s each independently are 0, 1, 2, 3, 4, 5, or 6 and Z is O, S, CH2 or NR"" wherein R"" is hydrogen, alkyl, or --(CH2)p --W, wherein p is 0, 1, 2, 3, 4, 5, or 6, and W is hydroxy, amino, alkoxycarbonyl, or phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, NO2, amino, alkyl, alkoxy or methylenedioxy; and wherein R'" is hydrogen, alkyl, alkoxy or phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, NO2, amino, alkyl, alkoxy or methylenedioxy; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b. The compounds are useful in the treatment of cerebrovascular disorders for example.
-
(2008/06/13)

AMPA antagonists and method of treatment therewith
The present patent application discloses compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R 1 is hydrogen, alkyl or benzyl; X is O or NOR 2, wherein R 2 is hydrogen, alkyl or benzyl; Y is N--R 4 wherein R 4 is hydrogen, OH or alkyl; n is 0 or 1; R 6 is phenyl, naphthyl, thienyl, pyridyl, all of which may be substituted one or more times with substituents selected from the group consisting of halogen; CF 3, NO 2, amino, alkyl, alkoxy and phenyl; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b. The compounds are useful in the treatment of cerebrovascular disorders for example. STR1
-
(2008/06/13)

Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: Characterization of α- amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D- aspartate) receptor and anticonvulsant activ
Four related series of substituted quinoxalinediones containing angular fused-piperidine rings have been synthesized as α-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid (AMPA) receptor antagonists with potential as neuroprotective agents, primarily f
Bigge,Malone,Boxer,Nelson,Ortwine,Schelkun,Retz,Lescosky,Borosky,Vartanian,Schwarz,Campbell,Robichaud,Watjen
p. 3720 - 3740
(2007/10/02)

Isatineoxime derivatives, their preparation and use
A compound having the formula STR1 wherein R4 and R5 independently are hydrogen, halogen, CF3, CN, NO2 or SO2 NR1 R2 wherein R1 is hydrogen or C1-6 -alkyl w
-
(2008/06/13)

Novel isatineoxime derivatives, their preparation and use
From EXEMP_CLAIMS : 1. A chemical compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein, R4 and R5 independently represent hydrogen, halogen, CF3, CN, NO2 or a group of the formula SO2NR1R2 wherein R1 and R2 independently represent hydrogen, C1-C6-alkyl which may be straight or branched, or C3-C7-cycloalkyl, and RII represents hydrogen, benzyl, -(C=O)CF3, C1-6-carboxylic acid acyl, C1-C6-alkoxy, C1-C6-alkyl which may be straight or branched, or CH2CO2RVI wherein RVI represents hydrogen or C1-C6-alkyl which may be straight or branched.
-
(2008/06/13)

190. Synthese einiger 8-substituierter 2-Methyl-1,2,3,4-tetrahydroisochinoline
A general route to 8-substituted tetrahydroisoquinolines is exemplified by preparetion of the 2-methyl-1,2,3,4-tetrahydroisoquinolin-8-ol (11), the -8-carbaldehyde oxime (12) and the -8-carbonitrile (13).It involves the conversion of isoquinoline (1) by partially modified Steps 1,2,3, and 5 (see the Scheme) into the 5-bromo-8-nitro derivative 5, reduction of the latter to the 8-amino derivative 8 and replacement of the NH2-group with an appropriate substituent by a Sandmeyer-like reaction.The selective reductions of the N-containing ring in 6 (Steps 5,6, and 8) and of the NO2-group in 5 (Steps 4 and 7) were also studied.
Rey, Max,Vergnani, Tiziana,Dreiding, Andre S.
p. 1828 - 1834
(2007/10/02)